Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2009 |
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Rationale: Giving colony-stimulating factors, such as G-CSF and plerixafor helps stem cells
move from the patient's bone marrow to the blood so they can be collected and stored.
Purpose: This phase II trial is studying how well plerixafor works in patients with multiple
myeloma previously treated with lenalidomide and planning to undergo autologous stem cell
transplant.
Primary Objective: I. To determine the proportion of patients reaching a stem cell yield of
3 million CD34 cells/kg by second day of apheresis with intravenously administered AMD3100
among patients receiving primary therapy for myeloma with lenalidomide. Secondary
Objectives: I. Safety and tolerability of intravenously administered AMD3100. II. Rate of
failure to mobilize. Outline: Patients receive plerixafor IV on days 5-8 and filgrastim
subcutaneously on days 1-8 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 30 days.
We found this trial at
2
sites
Mayo Clinic Scottsdale Mayo Clinic Arizona was the second Mayo practice to be established outside...
Click here to add this to my saved trials
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials